NEW YORK (360Dx) – BioMérieux announced today that it has increased its holding in Suzhou Hybiome Biomedical Engineering, an immunoassay maker based in Suzhou, China.
The firm acquired a majority stake in Hybiome last year, and has now increased its stake from 54 percent to 67 percent, according to a statement.
Hybiome develops, manufactures, and markets a range of diagnostic solutions, including reagents, instruments, and software that are cleared by the National Medical Products Administration, an agency formerly known as the China Food and Drug Administration.
BioMérieux previously noted that Hybiome markets two automated mid-throughput immunoassay systems with menus of about 80 assays, and that the company has an installed base of approximately 1,000 instruments, primarily in mid-size hospitals.
BioMérieux has offices in six locations in China, including Shanghai, Beijing, Chengdu, Guangzhou, Suzhou, Hong Kong and Taipei, and the country is the firm's second largest business area in terms of revenue, it said.